We support policies that promote cautious, evidence-based prescribing of opioids and other controlled drugs.
PROP JOINED OTHER GROUPS PETITIONING THE FDA FOR REMOVAL OF ULTRA HIGH DOSAGE UNIT OPIOIDS
On August 31, 2017, International Overdose Awareness Day, PROP joined the Association of State and Territorial Health Officials (ASTHO), the FED UP! Coalition, National Safety Council and Shatterproof in a petition to the FDA for the removal of ultra high dosage opioids from the market.
PROP URGES FDA TO FIX OPIOID REMS PRESCRIBER CURRICULUM
CMS responds to PROP petition on patient satisfaction
We are pleased to announce that CMS has agreed to remove the financial incentive for prescribing pain medication. Starting in October 2017, scores on the pain medication questions will be removed from Hospital Value-Based Purchasing Program. CMS wrote in its letter to PROP, “We believe this will help eliminate any unintended confusion and pressure to overprescribe pain medication.”
We are grateful to the all the hospitalists, emergency medicine docs, nurses and other folks who brought this issue to PROP’s attention.
Joint Commission Responds Defensively to PROP Request for revised pain standards
Last spring, when PROP petitioned CMS, the same coalition of organizations, state health officials, and medical experts sent The Joint Commission (TJC) a letter requesting revisions to their pain standards. Unfortunately, TJC responded defensively to our request. It issued public statements denying any relationship between its Pain Management Standards and opioid overprescribing.
TJC even denied having participated in the ‘Pain is the Fifth Vital Sign’ campaign, which is strange because the slogan was used in widely distributed Joint Commission materials.
The Opioid Lobby Spent $880 Million to Influence Federal and State Government
The Associated Press and the Center for Public Integrity teamed up to investigate the influence of pharmaceutical companies on state and federal policies regarding opioids. The news agencies tracked proposed laws on the subject and analyzed data on how the companies and their allies deployed lobbyists and contributed to political campaigns. Findings from their investigation were published as a two-part series carried by newspapers across the US and abroad. You can click here to learn more about the investigation.
PROP petitions CMS for removal of the HCAHPS pain questions
HCAHPS Letter- Final 04 11 16
Pursuant to section 553(e) of the Administrative Procedure Act, the undersigned organizations and individuals submit this Petition requesting that the Centers for Medicare and Medicaid Services (CMS) remove questions pertaining to pain treatment from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey.
PROP organizes coalition seeking changes to Joint Commission’s Pain Standards
TJC Letter – Final 04 11 16
The undersigned organizations and individuals are writing to request that the Joint Commission reexamine the Pain Management Standards (PC.01.02.07, PC.01.02.01 RI.01.01.01). Although we commend TJC for its recent clarification of PC.01.02.07, affirming that treatment strategies may include non-pharmacological approaches, we believe the Pain Management Standards continue to encourage unnecessary, unhelpful and unsafe pain treatments that interfere with primary disease management.
Bill to de-link HCAHPS pain questions from hospital reimbursement, PROP Act, receives bi-partisan support
Sen. Ron Johnson (R-Wis.), joined by his colleagues Sens. Joe Manchin (D-W.Va.), John Barrasso (R-Wyo.) and Richard Blumenthal (D-Conn.), introduced legislation Thursday to reduce the pressure doctors currently face that may lead to overprescribing painkilling drugs called opioids.
PROP comments on the draft National Pain Strategy
Last May, PROP submitted a comment to the National Institutes of Health on its proposed National Pain Strategy. We objected to the proposal for a so-called “safe use campaign” for opioid prescribing and instead called for an educational campaign that discourages opioid use for conditions where risks are likely to outweigh benefits.
PROP’s position on Federal Bills
Bipartisan legislation introduced by Senator Joe Manchin (D-WVa) on April 15, 2015. Co-sponsors include Tim Kaine (D-Va), David Vitter (R-LA) and Shelley Moore Capito (R-WVa). The bill requires the FDA to establish an advisory panel for each application submitted to the FDA for approval of an opioid drug and report to congress any instance where approval is recommended when inconsistent with the advice of the panel. A drug approved inconsistent with the recommendations of the advisory panel shall not be introduced or delivered for introduction into interstate commerce until the report describing the approval has been submitted to Congress.
Bipartisan legislation introduced on July 30, 2015, by Senator Pat Toomey (R-PA) with co-sponsors Joe Manchin (D-WVa), Tim Kaine (D-VA), Sherrod Brown (D-OH), Rob Portman (R-OH). This bill would authorize the use of patient review and restriction (PRR) programs in Medicare, which can help prevent prescription drug abuse among beneficiaries. The use of PRR programs will assign patients who are at-risk for opioid dependence to predesignated pharmacies and prescribers to better manage appropriate care and monitor prescriptions of opioid drugs for Medicare beneficiaries.
The bill would limit the DEA from suspending the registrations of entities that pose an “imminent danger to the public health or safety.” This bill was lobbied for by corporations that distribute and sell opioid analgesics. We are opposed because it limits the authority of the DEA to suspend the registration of DEA registrants (manufacturers, wholesalers, retailers, pain clinics) who may be putting the public at risk.
This bill is bipartisan legislation introduced by U.S. Senators Edward Markey (D-Mass) and Rand Paul (R-Ky) on May 22, 2015, which will expand treatment for those suffering from prescription drug and heroin addiction. A companion bill was introduced in the House of Representatives by Representatives Brian Higgins (D-N.Y.), Richard Hanna (R-N.Y.), Paul Tonko (D-N.Y.), and John Katko (R-N.Y.). The legislation would expand the ability of addiction medical specialists and other trained medical professionals to provide life-saving medication-assisted therapies such as buprenorphine for patients battling opiate addiction. The bill will raise the limits on the number of patients a physician or nurse practitioner may treat from 30 to 100 in the first year and with no limit thereafter. Those providing treatment must receive additional training in addiction, use the Prescription Drug Monitoring Program (PDMP) and administer treatment in a qualified practice setting with defined oversight.
This legislation was re-introduced on February 15, 2015, by U.S. Senators Sheldon Whitehouse (D-RI) and Rob Portman (R-OH) and was co-sponsored by 13 additional Senators. A House of Representatives companion bill, HR 953 has also been introduced. This legislation will expand prevention and education efforts, expand access to the overdose-reversing drug Naloxone, support alternative treatment in lieu of incarceration, strengthen the Prescription Drug Monitoring Program and support expansion of the use of evidence-based treatment medications. CARA 2015 designates up to $80 million toward these efforts.
Bipartisan legislation introduced on June 23, 2015, by Senators Harry Reid (D-NV) and Dick Durbin (D-IL) with co-sponsors Leahy (D-VT), Markey (D-MA) and Whitehouse (D-RI). Companion bill offered in the House by Representative Edwards (D-MD), Carney (D-DE) and others. This bill amends the PHS Act to require SAMHSA to enter into cooperative agreements to purchase and distribute naloxone and to distribute education materials to the public, first responders, and health professionals on overdose prevention and response.
Bipartisan legislation introduced on March 11, 2015, sponsored by Senator Ed Markey (D-MA) with co-sponsors Kelly Ayotte (R-NH), Tim Kaine (D-VA) and Pat Toomey (R-PA). The bill limits civil liability for health care professionals who prescribe or provide naloxone and to trained laypersons who administer it in an overdose event. Companion bill introduced in the House by Representatives Neal (D-MA), Guinta (R-NH) and Comstock (R-VA).
Bipartisan legislation introduced on March 19, 2015, by Senator Mitch McConnell (R-KY) and Casey (D-PA) with co-sponsors Kelly Ayotte (R-NH), Rob Portman (R-OH) and others. Companion bill introduced in the House by Representative Clark (D-MA) with 72 co-sponsors. This bill requires the Agency for Healthcare Research and Quality to report on prenatal opioid abuse and neonatal abstinence syndrome (symptoms of withdrawal in a newborn). The report must include an assessment of existing research on neonatal abstinence syndrome, an evaluation of the causes, and barriers to treatment, an evaluation of treatment for pregnant women with opioid use disorders and infants with neonatal abstinence syndrome, and recommendations on preventing, identifying, and treating opioid dependency in women and neonatal abstinence syndrome. HHS is directed to develop a strategy to address gaps in research and programs and the CDC must provide technical assistance to states to improve neonatal abstinence syndrome surveillance and make surveillance data publicly available.